CD4+CD25-Foxp3+ T cells: A marker for lupus nephritis?

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Bonelli, Michael ^a   Göschl, Lisa ^a   Blüml, Stephan ^a   Karonitsch, Thomas ^a   Steiner, Carl Walter ^a   Steiner, Günter ^a   Smolen, Josef S ^a   Scheinecker, Clemens ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CHLOROQUINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; FORKHEAD TRANSCRIPTION FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; SLEDAI; T LYMPHOCYTE SUBPOPULATION; URINE SEDIMENT; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CLINICAL FEATURE; HUMAN CELL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; BLOOD; CD4+ T LYMPHOCYTE; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PHENOTYPE;

ADULT; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 84902117788     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4553     Document Type: Article

References (34)

1. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4 + CD25 high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253. 10.4049/jimmunol.167.3.1245, 11466340.
2. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985, 161:72-87. 10.1084/jem.161.1.72, 2187548, 3871469.
3. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440. 10.1016/S1074-7613(00)80195-8, 10795741.
4. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001, 182:58-67. 10.1034/j.1600-065X.2001.1820104.x, 11722623.
5. Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun 2001, 16:115-123. 10.1006/jaut.2000.0473, 11247637.
6. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302. 10.1084/jem.192.2.295, 2193261, 10899916.
7. Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008, 20:861-868. 10.1093/intimm/dxn044, 18469329.
8. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol 2008, 28:677-684. 10.1007/s10875-008-9242-z, 18716861.
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
10. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, Huehn J, Hori S. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012, 36:262-275. 10.1016/j.immuni.2011.12.012, 22326580.
11. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336. 10.1038/ni904, 12612578.
12. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
13. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011, 241:260-268. 10.1111/j.1600-065X.2011.01018.x, 3077798, 21488902.
14. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226. 10.1146/annurev.immunol.24.021605.090547, 16551248.
15. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010, 184:3433-3441. 10.4049/jimmunol.0904028, 3725574, 20181882.
16. Kim YC, Bhairavabhotla R, Yoon J, Golding A, Thornton AM, Tran DQ, Shevach EM. Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 2012, 119:2810-2818. 10.1182/blood-2011-09-377895, 3327459, 22294730.
17. Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3 + Helios + Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 2013, 65:2898-2906. 10.1002/art.38119, 3891045, 23925905.
18. Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol 2009, 182:1689-1695. 10.4049/jimmunol.182.3.1689, 19155519.
19. Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE. Clinical significance of increased CD4 + CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 2008, 67:1037-1040. 10.1136/ard.2007.083543, 18199598.
20. Yan B, Liu Y. The nature of increased circulating CD4CD25Foxp3 T cells in patients with systemic lupus erythematosus: a novel hypothesis. Open Rheumatol J 2009, 3:22-24. 10.2174/1874312900903010022, 2705839, 19590592.
21. Yang HX, Zhang W, Zhao LD, Li Y, Zhang FC, Tang FL, He W, Zhang X. Are CD4 + CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. Arthritis Res Ther 2009, 11:R153. 10.1186/ar2829, 2787292, 19821980.
22. Prado C, de Paz B, Lopez P, Gomez J, Rodriguez-Carrio J, Suarez A. Relationship between FOXP3 positive populations and cytokine production in systemic lupus erythematosus. Cytokine 2012, 61:90-96.
23. Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009, 127:196-205. 10.1111/j.1365-2567.2008.02937.x, 2691785, 18800986.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
26. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10:541-547.
27. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10:549-554.
28. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009, 18:220-225. 10.1097/MNH.0b013e328327b379, 19374008.
29. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003, 21:273-276. 10.1016/S0896-8411(03)00121-5, 14599852.
30. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4 + CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007, 601:113-119. 10.1007/978-0-387-72005-0_12, 17712998.
31. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008, 17:289-294. 10.1177/0961203307088307, 18413409.
32. Suarez A, Lopez P, Gomez J, Gutierrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006, 65:1512-1517. 10.1136/ard.2005.049924, 1798359, 16606650.
33. Azab NA, Bassyouni IH, Emad Y, Abd El-Wahab GA, Hamdy G, Mashahit MA. CD4 + CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clinical immunology 2008, 127:151-157. 10.1016/j.clim.2007.12.010, 18299252.
34. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 2007, 37:987-996. 10.1111/j.1365-2362.2007.01882.x, 18036033.